ArticleBritish journal of cancer2013
Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis.Clinical and experimental medicine · 2024Pooled it
- Liquid biopsy for gastric cancer: Techniques, applications, and future directions.World journal of gastroenterology · 2024Review
- Circulating tumor cells in gastric cancer: developments and clinical applications.Clinical and experimental medicine · 2023Review
- Nanotechnology and machine learning enable circulating tumor cells as a reliable biomarker for radiotherapy responses of gastrointestinal cancer patients.Biosensors & bioelectronics · 2023Article
- Review
- Clinical Significance of Circulating Tumor Cells in Gastrointestinal Carcinomas.Diagnostics (Basel, Switzerland) · 2020Review
- HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies.Journal of personalized medicine · 2020Review
- Review
- Clinical Application of Circulating Tumor Cells in Gastric Cancer.Gut and liver · 2019Review
- Liquid biopsy provides new insights into gastric cancer.Oncotarget · 2018Review
- ERBB signaling in CTCs of ovarian cancer and glioblastoma.Genes & cancer · 2017Review
- Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion.Oncotarget · 2017Review
- Expression and Clinical Significance of Cytokeratin-19 and Thymidine Kinase-1 in Advanced Gastrointestinal Cancer.Chinese medical journal · 2016Article
- Potentiated DNA Damage Response in Circulating Breast Tumor Cells Confers Resistance to Chemotherapy.The Journal of biological chemistry · 2015Article
- Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer.Oncotarget · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical significance of circulating tumour cell (CTC) detection in gastrointestinal (GI) cancer remains controversial and the molecular biological characteristics of CTCs are poorly understood.
methodsA total of 87 patients with metastatic or recurrent GI cancer were prospectively enrolled. Circulating tumour cells and their HER2 status were assessed using the CellSearch System.
resultsAmong the 62 CTC-positive cases, we found 22 discordant cases (35.5%). Among the HER2-negative primary tumours, 17 of 54 developed HER2-positive CTCs. Five of eight had HER2-negative CTCs among the HER2-positive primary tumours.
conclusionThe findings in the current study suggest that it is critical to evaluate the HER2 status of not only the primary tumour but also the CTCs because the metastasising tumour cells are the primary target of systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.